Sonnet BioTherapeutics
SONN
SONN
22 hedge funds and large institutions have $2.26M invested in Sonnet BioTherapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0% more ownership
Funds ownership: 0% → 0% (+0%)
Holders
22
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$551K | |
| 2 | +$153K | |
| 3 | +$147K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$77K |
| 5 |
CAM
Campion Asset Management
Falls Church,
Virginia
|
+$34K |
Top Sellers
| 1 | -$173K | |
| 2 | -$53K | |
| 3 | -$35.2K | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$19K |
| 5 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$7K |